Nuvalent Shares Outstanding 2021-2024 | NUVL

Nuvalent shares outstanding for the quarter ending December 31, 2024 were 0.066B, a 14.06% increase year-over-year.

  • Nuvalent 2024 shares outstanding were 0.066B, a 14.06% increase from 2023.
  • Nuvalent 2023 shares outstanding were 0.058B, a 17.22% increase from 2022.
  • Nuvalent 2022 shares outstanding were 0.05B, a 128.01% increase from 2021.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Nuvalent Shares Outstanding 2021-2024 | NUVL

  • Nuvalent 2024 shares outstanding were 0.066B, a 14.06% increase from 2023.
  • Nuvalent 2023 shares outstanding were 0.058B, a 17.22% increase from 2022.
  • Nuvalent 2022 shares outstanding were 0.05B, a 128.01% increase from 2021.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B